Published in J Biol Chem on August 11, 2003
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog (2007) 2.98
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol (2007) 2.29
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One (2008) 1.86
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol (2006) 1.62
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog (2007) 1.56
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A (2004) 1.48
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog (2012) 1.41
Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol (2006) 1.39
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol (2010) 1.39
HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol (2011) 1.37
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol (2006) 1.35
Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 1.34
Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. J Virol (2005) 1.34
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Domain II loop 3 of Bacillus thuringiensis Cry1Ab toxin is involved in a "ping pong" binding mechanism with Manduca sexta aminopeptidase-N and cadherin receptors. J Biol Chem (2009) 1.32
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Hepatitis C virus proteins. World J Gastroenterol (2007) 1.28
Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathog (2010) 1.26
Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol (2006) 1.25
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol (2007) 1.24
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol J (2008) 1.21
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J (2006) 1.19
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol (2012) 1.18
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Tetraspanins in viral infections: a fundamental role in viral biology? J Virol (2005) 1.16
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol (2009) 1.14
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol (2008) 1.12
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut (2005) 1.11
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis. J Virol (2005) 1.11
CLA-1 and its splicing variant CLA-2 mediate bacterial adhesion and cytosolic bacterial invasion in mammalian cells. Proc Natl Acad Sci U S A (2006) 1.10
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol (2009) 1.07
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am J Pathol (2006) 1.04
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One (2013) 1.03
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res (2012) 1.03
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem (2012) 1.03
Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J (2009) 1.01
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol (2012) 0.97
Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay. J Virol (2006) 0.97
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
Structural biology of hepatitis C virus. Hepatology (2004) 3.40
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO J (2002) 3.11
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem (2005) 2.31
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol (2003) 2.03
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 2.02
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol (2006) 1.96
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther (2011) 1.92
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A (2007) 1.89
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol (2002) 1.89
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One (2008) 1.86
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis (2012) 1.85
Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 1.85
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther (2012) 1.76
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther (2002) 1.73
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol (2007) 1.69
Cell cycle features of primate embryonic stem cells. Stem Cells (2005) 1.64
The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol (2008) 1.63
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One (2012) 1.58
Cell entry of hepatitis C virus. Virology (2006) 1.58
Glycosylation of hepatitis C virus envelope proteins. Biochimie (2003) 1.56
Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg (2005) 1.56
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol (2010) 1.55
A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc (2011) 1.54
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog (2011) 1.52
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. EMBO J (2002) 1.52
Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum Gene Ther (2002) 1.50
The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors. J Virol (2002) 1.49
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J Biol Chem (2004) 1.49
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol (2009) 1.43
Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem (2005) 1.41
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem (2004) 1.41
Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol (2008) 1.41
A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly. PLoS Pathog (2011) 1.41
Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol (2004) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol (2003) 1.38
Transduction of nondividing human macrophages with gammaretrovirus-derived vectors. J Virol (2006) 1.38
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37